Answer
Tildrakizumab does not affect the pharmacokinetics of concomitant medicines metabolised by CYP450 enzymes through either direct or indirect mechanisms.
Sources for this answer
- Ilumetri 100 mg solution for injection in pre-filled syringeAlmirall Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 6Document updated
Sources checked